In 2010, the NCCN guideline suggested that BRCA1/2 testing was indicated for women with TNBC who were younger than 40 years, based on emerging evidence that the triple‐negative phenotype was associated with hereditary cancer syndromes regardless of family history 16, 17. Here, BRCA1 is linked to Inherited cancer-predisposing syndrome.